Obesity rates have surged globally, with more individuals now classified as overweight than malnourished, highlighting the urgent need for effective treatments such as GLP-1 drugs like Ozempic and Wegovy.

Both Ozempic and Wegovy, produced by Novo Nordisk, are GLP-1 drugs that not only facilitate weight loss by helping individuals feel fuller but also offer additional health benefits.

In the UK, the annual cost of a supply of Ozempic is approximately £830, while Wegovy is significantly more expensive at £2,760; these prices are even higher in the US.

Healthcare costs associated with obesity average around €1,700 per person in the UK, with notable variations in costs across Germany, the Netherlands, and the US.

The total annual economic burden of obesity in the UK is estimated at £100 billion, with the National Health Service (NHS) covering about £19 billion of that cost.

Healthcare costs represent roughly 25% of the total economic burden of obesity, which also encompasses productivity losses and personal expenses incurred by individuals struggling with this condition.

Obesity is linked to severe health issues, including cardiovascular diseases and diabetes, which contribute to high treatment costs and further strain healthcare systems.

Research from the Institute for Advanced Studies in Vienna indicates that individuals with obesity are twice as likely to take sick leave, exacerbating labor shortages in Europe.

A recent report emphasizes that the economic costs of obesity far exceed the expenses associated with new weight-loss drugs, urging governments to prioritize prevention through diet and exercise.

While doctors often prescribe weight-loss drugs alongside lifestyle changes, there is a growing call for governments to implement policies, such as tax incentives, to encourage healthier eating habits.

Experts predict that as more options for obesity drugs enter the market, prices may decrease, but immediate government action is essential to support at-risk populations.

Despite the potential benefits of obesity drugs, the long-term efficacy remains uncertain, with studies indicating significant weight regain after discontinuation and possible side effects.